Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1996-11-12
1998-09-08
Knode, Marian
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530385, 530829, 424529, 424530, A61K 3702, A61K 3514
Patent
active
058045511
ABSTRACT:
A method for improving recovery after surgery or an invasive procedure is provided, including administering a hemoglobin preparation to a patient before surgery or an invasive procedure.
REFERENCES:
patent: 4911929 (1990-03-01), Farmer et al.
patent: 4994444 (1991-02-01), Zikria
patent: 5295944 (1994-03-01), Teicher et al.
patent: 5296466 (1994-03-01), Kilbourn
patent: 5334706 (1994-08-01), Przybelski
patent: 5344393 (1994-09-01), Roth et al.
patent: 5428007 (1995-06-01), Fischer et al.
patent: 5432191 (1995-07-01), Abraham et al.
patent: 5451205 (1995-09-01), Roth et al.
patent: 5478806 (1995-12-01), Nho
patent: 5498421 (1996-03-01), Grinstaff et al.
patent: 5571801 (1996-11-01), Segall et al.
Zauder Anethesiology Clinics of North America 8(3): 471-479, 1990.
Rabinovici et al. Circulatory Shock 29:115-132, 1989.
Gulati et al. Life Sciences 55(1):827-837, 1994.
Dietz et al. Anesth. Analg 82:390-405, 1996.
Garrioch et al. Crit Care Med 24(1): A39 (Abstract), 1996.
Farmer, Hemoglobin-Based Therapeutics: Trials Show Real Potential, Technical Forum-Therapeutics, (2 pages), Reprinted from the Biotechnology Report 1994/95.
Farmer et al., Preclinical Data and Clinical Trials with Diaspirin Cross-linked Hemoglobin, Artif. Red Cells, pp. 177-185, 1995.
Fukushima et al., Clinical Experience of Hemodilution with Fluosol-DA, Jpn. J. Anesthesiol. (Japan), vol. 30, No. 7, pp. 741-745, 1981.
Giordano et al., An Autologous Blood Program Coordinated by a Regional Blood Center: A 5-Year Experience, Transfusion, vol. 31, No. 6, pp. 509-512, 1991.
Greenwalt et al., Perioperative Red Blood Cell Transfusion, J. Amer. Med. Assoc., vol. 260, No. 18, pp. 2700-2703, 1988.
Messmer et al., Present State of International Hemodilution, Eur. Surg. Res., vol. 18, pp. 254-263, 1986.
Przybelski et al., Clinical Studies with Diaspirin Cross-Linked Hemoglobin Solution (DCLHb): A Review and Update, Art. Cells, Blood Subs., and Immob. Biotech., vol. 24, No. 4, p. 407, 1996 (abstract).
Stehling et al., Acute Normovolemic Hemodilution, Transfusion, vol. 31, No. 9, pp. 857-868, 1991.
Zauder, Preoperative Hemoglobin Requirements, Anesthesiology Clinics of North America, vol. 8, No. 3, pp. 471-480, 1990.
Zietlow, An Overview of DCLHb and Blood Substitutes, 8th European Congress of Intensive Care Medicine, Greece, pp. 813-816, 1995.
Zuck et al., Autologous Transfusion Practice, Vox Sang, vol. 58, pp. 234-253, 1990.
Slanetz et al., "Hemoglobin Blood Substitutes in Extended Preoperative Autologous Blood Donation: An Experimental Study," Surgery, vol. 115, No. 2, pp. 246-254, 1994.
Otterbein et al., "Hemoglobin Provides Protection Against Lethal Endotoxemia in Rats: The Role of Heme Oxygenase-1," Am. J. Respir. Cell Mol. Biol., vol. 13, pp. 595-601, 1995.
Alayash, "Hemoglobin and Tissue Oxidants: Physiological Implications and Protective Strategies,"Artificial Cells, Blood Substitutes, and Immobilization Biotechnology, vol. 24, No. 4, p. 298, (abstract), 1996.
Rhea et al., "Vasopressor Effects of Diaspirin Cross-Linked Hemoglobin (DCLHb) in Critically Ill Patients," Critical Care Medicine, vol. 24, No. 1, p. 3 (abstract), 1996.
Simoni et al., "Immunohistochemical Evaluation of Adhesion Molecules and Von Willebrand Factor Expression in Human Coronary Artery Endothelial Cells Incubated with Different Hemoglobin Solutions," Artificial Cells, Blood Substitutes, and Immobilization Biotechnology, vol. 24, No. 4, p. 428 (abstract), 1996.
Simoni et al., "Modified Hb Solution, with Low Prooxidant Potential and Desired Pharmacological and Anti-Inflammatory Properties, Does Not Activate the Transcription Factor NF-kappa B in Human Vascular Endothelial Cells," Artificial Cells, Blood Substitutes, and Immobilization Biotechnology, vol. 24, No. 4, p. 429, (abstract), 1996.
Vercellotti, "Vascular Responses to Hemoglobin Derived Iron: Potential Dangers and Cytoprotective Adaptions," Artificial Cells, Blood Substitutes, and Immobilization Biotechnolgy, vol. 24, No. 4, p. 451, (abstract), 1996.
Baxter International Inc.
Knode Marian
Williams Jay F.
LandOfFree
Pretraumatic use of hemoglobin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pretraumatic use of hemoglobin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pretraumatic use of hemoglobin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1282193